Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $64.30 USD
Change Today 0.00 / 0.00%
Volume 0.0
CHGCY On Other Exchanges
Symbol
Exchange
Tokyo
OTC US
OTC US
Frankfurt
As of 8:10 PM 04/22/15 All times are local (Market data is delayed by at least 15 minutes).

chugai pharmaceutic-unsp adr (CHGCY) Key Developments

Chugai Pharmaceutical Co. Ltd., Board Meeting, Apr 22, 2015

Chugai Pharmaceutical Co. Ltd., Board Meeting, Apr 22, 2015. Agenda: To amend basic policies concerning internal controls.

Chugai Pharmaceutical Co. Ltd. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015; Reaffirms Consolidated Earnings Guidance for the Year Ending December 31, 2015

Chugai Pharmaceutical Co. Ltd. reported unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported core and IFRS revenues of JPY 117,083 million compared to JPY 124,045 million a year ago. Operating profit was JPY 20,750 million compared to JPY 31,089 million a year ago. Profit before taxes was JPY 21,174 million compared to JPY 31,263 million a year ago. Net income was JPY 14,819 million compared to JPY 19,080 million a year ago. Net income attributable to the shareholders was JPY 14,582 million compared to JPY 18,776 million a year ago. Diluted net income per share was JPY 26.68 compared to JPY 34.41 a year ago. Core operating profit was JPY 27.54 per share. Core operating profit was JPY 21.5 billion against JPY 31.4 billion last year, a decrease of 31.5% year on year. Core net income was JPY 15.3 billion against JPY 19.3 billion last year, a decrease of 20.7% year on year, due to the improvements in other financial income (expense) and the reduction of the tax burden ratio due mainly to the changes in the taxation system. Cash flows from operating activities were JPY 33.3 billion compared to JPY 15.4 billion last year. Free cash flows were JPY 10.8 billion against negative free cash flows of JPY 3.6 billion last year. Purchase of property, plant and equipment was JPY 5.1 billion against JPY 5.6 billion last year. Purchase of intangible assets was JPY 2.1 billion against JPY 721 million last year. Ratio of net income to equity attributable to Chugai shareholders (ROE) was 2.5% against 3.3% last year. Ratio of profit before taxes to total assets (ROA) was 2.9% against 4.5% last year. Core return on net operating assets (core RONOA) was 4.5% against 5.8% last year. Core profit before taxes was JPY 21.9 billion compared to JPY 31.6 billion a year ago. Core net income attributable to the shareholders was JPY 15.1 billion against JPY 19.0 billion last year. Core earnings per diluted share were JPY 27.54 against JPY 34.82 last year. On consolidated basis, the company reaffirmed earnings guidance for the year ending December 31, 2015. The company expects revenues of JPY 486,500 million, core operating profit of JPY 85,000 million and core earnings per share of JPY 104.42. The company expecting 5.5% growth in sales compared to the previous year. The company forecasting JPY 0.7 billion sales for the remaining 9 months this year.

Chugai Pharmaceutical Co. Ltd., Q1 2015 Earnings Call, Apr 22, 2015

Chugai Pharmaceutical Co. Ltd., Q1 2015 Earnings Call, Apr 22, 2015

Chugai Pharmaceutical Co. Ltd. to Report Q1, 2015 Results on Apr 22, 2015

Chugai Pharmaceutical Co. Ltd. announced that they will report Q1, 2015 results at 4:30 PM, Tokyo Standard Time on Apr 22, 2015

Chugai Pharmaceutical Co., Ltd. and Taisho Pharmaceutical Co., Ltd. Announce Positive Results from Phase III Osteoporosis Trial

Chugai Pharmaceutical Co., Ltd. and Taisho Pharmaceutical Co., Ltd., have announced positive results from Japanese Phase III clinical trial of a bisphosphonate antiresorptive agent, ibandronate sodium hydrate oral agent, which is currently co-developed by Chugai and Taisho in Japan for the anticipated indication of osteoporosis. The MOVEST study, a randomized, multi center, double-blind, parallel group, controlled study, was conducted in approximately 400 patients (over 55 years of age) with osteoporosis to assess efficacy and safety of ibandronate oral formulation 100mg against ibandronate sodium hydrate injection [brand name: Bonviva IV Injection 1 mg Syringe (ibandronate injection)]. The increase in bone mineral density (BMD) of the lumbar spine (L2-L4) (percentage of relative change from baseline) at twelve month, the study's primary endpoint, was 5.22% for ibandronate oral formulation, and 5.34% [ 95% CI: 4.78% - 5.90% ] for ibandronate injection, respectively. The difference between the rate of change for ibandronate injection group of ibandronate oral formulation group (least squeares meane) was -0.23. It met the protocol criteria, a non-inferiority of ibandronate oral formulation to ibandronate injection has been demonstrated. The secondary endpoints of BMD gains in femur and inhibition on bone metabolic markers also showed similar effects between the two groups. No new safety signals were observed in the study. The safety profile was consistent with the previous overseas study results, and well tolerability of ibandronate oral formulation in osteoporotic patients was observed. Chugai filed a new drug application to the Ministry of Health, Labour and Welfare in February 2015, based on above and other data. Chugai and Taisho have been co-developing ibandronate oral formulation and Bonviva IV Injection in Japan as new treatment options for osteoporosis that improve adherence and offer patients wider choice of administration routes in Japan. Chugai and Taisho Toyama Pharmaceutical Co., Ltd. have been co-marketing Bonviva IV Injection, developed ahead of ibandronate oral formulation, since August, 2013 after Chugai obtained approval for osteoporosis indication in June, 2013. Following Bonviva IV Injection, Chugai and Taisho are determined to make efforts to obtain early approval of ibandronate oral formulation, a monthly oral agent and supply to patients and healthcare professionals.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CHGCY:US $64.30 USD 0.00

CHGCY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $64.32 USD -0.34
Eli Lilly & Co $73.12 USD +1.25
Hospira Inc $87.29 USD 0.00
Merck KGaA €96.03 EUR -0.55
Teva Pharmaceutical Industries Ltd $62.17 USD +1.75
View Industry Companies
 

Industry Analysis

CHGCY

Industry Average

Valuation CHGCY Industry Range
Price/Earnings 43.3x
Price/Sales 4.5x
Price/Book 3.4x
Price/Cash Flow 44.4x
TEV/Sales 4.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CHUGAI PHARMACEUTIC-UNSP ADR, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.